Avalo Therapeutics, Inc. (NASDAQ:AVTX) Given Average Rating of “Moderate Buy” by Analysts
by Teresa Graham · The Cerbat GemAvalo Therapeutics, Inc. (NASDAQ:AVTX – Get Free Report) has received a consensus rating of “Moderate Buy” from the seven ratings firms that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, five have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among analysts that have covered the stock in the last year is $42.25.
Several equities analysts have weighed in on AVTX shares. Guggenheim began coverage on Avalo Therapeutics in a research report on Monday, February 2nd. They set a “buy” rating and a $50.00 price target for the company. Mizuho raised Avalo Therapeutics to a “strong-buy” rating in a research note on Thursday, December 18th. HC Wainwright lifted their price objective on Avalo Therapeutics from $25.00 to $40.00 and gave the stock a “buy” rating in a research report on Wednesday, March 25th. Wall Street Zen raised shares of Avalo Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Sunday, March 29th. Finally, BTIG Research reiterated a “buy” rating and set a $40.00 price target on shares of Avalo Therapeutics in a report on Tuesday, March 24th.
Check Out Our Latest Report on AVTX
Avalo Therapeutics Stock Performance
Shares of AVTX opened at $17.76 on Friday. Avalo Therapeutics has a 12-month low of $3.39 and a 12-month high of $20.72. The stock has a market cap of $404.75 million, a P/E ratio of -3.10 and a beta of 0.93. The company has a 50-day moving average of $15.54 and a two-hundred day moving average of $15.96.
Avalo Therapeutics (NASDAQ:AVTX – Get Free Report) last released its quarterly earnings results on Monday, March 23rd. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($1.54) by $1.17. The business had revenue of $0.06 million during the quarter, compared to analyst estimates of ($0.21) million. As a group, analysts forecast that Avalo Therapeutics will post -19.07 EPS for the current fiscal year.
Insider Activity at Avalo Therapeutics
In other Avalo Therapeutics news, CFO Christopher Ryan Sullivan sold 7,980 shares of the stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $17.15, for a total transaction of $136,857.00. Following the transaction, the chief financial officer owned 17,338 shares of the company’s stock, valued at $297,346.70. This represents a 31.52% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mittie Doyle sold 25,492 shares of Avalo Therapeutics stock in a transaction on Monday, March 16th. The shares were sold at an average price of $16.15, for a total value of $411,695.80. Following the completion of the sale, the insider directly owned 3,622 shares of the company’s stock, valued at approximately $58,495.30. This represents a 87.56% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 42,130 shares of company stock valued at $693,225 over the last ninety days. 3.03% of the stock is owned by corporate insiders.
Institutional Trading of Avalo Therapeutics
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. PFS Partners LLC lifted its holdings in shares of Avalo Therapeutics by 100.0% during the 4th quarter. PFS Partners LLC now owns 2,000 shares of the company’s stock worth $36,000 after acquiring an additional 1,000 shares during the period. BIT Capital GmbH purchased a new stake in Avalo Therapeutics in the third quarter valued at approximately $25,000. Geode Capital Management LLC increased its position in Avalo Therapeutics by 2.5% during the second quarter. Geode Capital Management LLC now owns 110,460 shares of the company’s stock worth $552,000 after purchasing an additional 2,648 shares during the last quarter. Quadrature Capital Ltd acquired a new position in Avalo Therapeutics during the second quarter worth approximately $55,000. Finally, Dimensional Fund Advisors LP purchased a new position in Avalo Therapeutics during the third quarter worth approximately $143,000. Hedge funds and other institutional investors own 87.06% of the company’s stock.
About Avalo Therapeutics
Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.
Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.